Clinical trials: Bladder
Over Active Bladder
Stimulating Percutaneous Array for Urinary Reflex Control (SPARC)
The Confidanz Smart Patch System consists of a Smart Patch containing one transcutaneous gel electrode and one percutaneous microneedle array electrode that sits directly superficial to the posterior tibial nerve.
- Trial name
- NCT07149103
- Testing
- Percutaneous Tibial Nerve Stimulation
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Australis Scientific PTY LTD
Bone Cancer, Brain Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing >10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants…
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer
- Trial name
- EARN (NCT06582849)
- Testing
- Standard assistance, Enhanced assistance
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Bladder (Urothelial, Transitional Cell) Cancer
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
This is a prospective, open label, multicenter clinical study of vediximab combined with PD-1 and radiation therapy for bladder preservation in MIBC patients with HER-2 high expression (IHC 2+or 3+), conducted in accordance with…
- Trial name
- DECIDING (NCT07142200)
- Testing
- Disitamab Vedotin, PD-1 inhibitor, radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital
Breast Cancer, Colorectal Cancer
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
Background: Chemotherapy-induced nausea and vomiting (CINV) is a common and burdensome side-effect of emetogenic chemotherapy. CINV affects both the patient's quality of life and induces high costs within the health-care system.
- Conditions
- Breast Cancer, Colorectal Cancer, Bladder Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- NCT03232541
- Testing
- Standard care, Genuine acupuncture
- Where
- Sweden
- Volunteers
- 198 people
- Sponsor
- Västernorrland County Council, Sweden
Muscle Invasive Bladder Cancer (MIBC)
MRI-Guided Bladder Preservation Program For Patients With Muscle Invasive Bladder Cancer
The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of bladder preservation as well as to decrease complications in patients with muscle invasive bladder cancer who wish to retain…
- Trial name
- NCT07026864
- Testing
- MR-guided Radiation Therapy
- Volunteers
- 31 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Bladder Cancer Requiring Cystectomy, Erectile Dysfunction Following Radical Prostatectomy
Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.
This pilot study will evaluate the safety and 1-year erectile function recovery in 10 patients undergoing a novel Nerve Restoring Radical Cystectomy (NR-RC), which includes a genitofemoral nerve graft.
- Trial name
- NR-RC (NCT07140588)
- Testing
- Patients undergoing radical cystectomy will receive a novel NR-RC procedure using a genitofemoral nerve graft to enhance erectile function recovery.
- Volunteers
- 10 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Bladder Urothelial Carcinoma, Urothelial Carcinoma
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with urothelial cancer undergoing surgery or biopsy.
- Trial name
- NCT03039413
- Testing
- Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Overactive Bladder
TENS Used for Pain Management During Office Cystoscopy Botox Injections
The purpose of this study is to determine how Transcutaneous Electric Nerve Stimulation (TENS) units affects pain management during office cystoscopic Botox injections and patient satisfaction with the procedure .
- Trial name
- NCT04448171
- Testing
- Active TENS
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Deep Learning, Ultrasound
Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
This study aims to develop an ultrasound image-based deep learning system to enable automatic segmentation, T-staging, and pathological grading prediction of bladder tumors.
- Conditions
- Deep Learning, Ultrasound, Bladder Cancer
- Trial name
- BCA-AI-US (NCT07111364)
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University First Hospital
Bladder Cancer, Radiation Cystitis
Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer
To evaluate the efficacy and safety of intravesical hyaluronic acid (HA) instillation therapy for the prevention of radiation-induced cystitis in patients undergoing radiotherapy for bladder cancer.
- Trial name
- NCT07125924
- Testing
- Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.), Normal Saline (NS)
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Bladder Cancer, Urinary Bladder Neoplasm
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation…
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms
- Trial name
- FMBRT (NCT04442724)
- Testing
- Fiducial marker placement, Multiparametric MRI (mpMRI)
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Bladder Cancer
Decision Making for Urinary Diversion in Patients With Bladder Cancer
This proposal will aim to improve the understanding about the treatment decision in the type of urinary diversion and identify patient knowledge gaps about uncertainty around patient decision-making.
- Trial name
- NCT05111639
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy.
- Conditions
- Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra, Urothelial Carcinoma Recurrent
- Trial name
- GRAPE (NCT06983210)
- Testing
- Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- Nagoya University
Non-muscle Invasive Bladder Cancer (NMIBC)
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG.
- Trial name
- NCT07122414
- Testing
- FL115, FL115+BCG
- Where
- 12 sites in China
- Volunteers
- 80 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Neurogenic Bladder Dysfunction
Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction
Many patients with neurological diseases suffer from neurogenic lower urinary tract dysfunction (NLUTD), which often severely impairs quality of life, due to urinary urgency with or without incontinence and voiding dysfunction.
- Trial name
- bTUNED (NCT04315142)
- Testing
- Experimental TTNS
- Where
- 12 sites in Belgium, Brazil and 2 more
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Bladder Cancer
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
In order to explore the safety and antitumor efficacy of different doses of CDK4/6 inhibitor Palbociclib in combination with the Tislelizumab in platinum-refractory cT2-4aN0M0 bladder urothelial carcinoma, a phase Ib/II study was…
- Trial name
- NCT06364956
- Testing
- Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
- Where
- 8 sites in China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Urinary Bladder, Overactive
The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia.
- Trial name
- NCT07114640
- Testing
- Mirabegron 25mg, Solifenacin 5 mg, Tolterodine 4 mg
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- Far Eastern Memorial Hospital